Table 1.
Candidate mAb dose expected to maintain concentration > IC90 over 14, 21, and 28 days for the typical patient and for 90% of patients
| mAb | Domain | ACE2 blocking | AC‐SINS score | Live virus IC50, ug/mL | Dose a , mg, expected to maintain concentration above live virus IC90 b in the lungs | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Geometric mean (min, max) | ||||||||||
| For a typical patient | For 90% of patients | |||||||||
| Day 14 | Day 21 | Day 28 | Day 14 | Day 21 | Day 28 | |||||
| 1 | S1 | No | 2·25 | 0.841 | 1,273 (918.7–2,303) | 1,664 (1,197–3,043) | 2,153 (1,542–3,988) | 3,295 (2,369–6,023) | 5,583 (3,981–10,440) | 9,236 (6,984–17,960) |
| 2 | RBD | Yes | 0 | 2.685 | 4,210 (2,607–11,580) | 5,662 (3,450–16,830) | 7,600 (4,534–25,280) | 11,190 (6,828–32,350) | 20,200 (11,890–67,670) | 37,020 (20,620–70,000) |
| 3 | NA | Yes | 0 | 1.3 |
1,977 NA |
2,599 NA |
3,387 NA |
5,145 NA |
8,838 NA |
14,990 NA |
| 4 | RBD | Yes | 0 | 1.112 | 1,684 (1,295–2,607) | 2,208 (1,692–3,450) | 2,867 (2,187–4,534) | 4,370 (3,349–6,828) | 7,446 (5,665–11,890) | 12,510 (9,370–20,620) |
| 5c | RBD | Yes | 1 | 0.04609 | 68.28 (25.16–237.5) | 88.16 (32.48–307.3) | 112.3 (41.38–392.2) | 174.3 (64.21–607.5) | 286.4 (105.4–1,002) | 454.9 (166.9–1,598) |
ACE2, angiotensin‐converting enzyme; AC‐SINS, affinity‐capture self‐interaction nanoparticle spectroscopy; IC50, half‐maximal inhibitory concentration; IC90, 90% inhibitory concentration; mAb, monoclonal antibody; NA, not applicable; Min, minimum; Max, maximum; S, spike protein; NTD, N‐terminus domain; RBD, receptor‐binding domain.
a
Dose for mAb 1, 2, 4, and 5 is the geometric mean of data from three assay laboratories. Data for mAb 3 was available from one assay laboratory only.
b
IC90 = 9 × IC50.
c
mAb 5 corresponds to bamlanivimab.